Now enrolling patients in the global Phase 3 CoMpass trial to evaluate the safety and efficacy of belzupacap sarotalocan (bel-sar) for the first-line treatment of adult patients with small choroidal melanoma or indeterminate lesions.
Board of Directors
« Back to Board of Directors

Karan Takhar

Karan Takhar is a Senior Managing Director and the head of Life Sciences investing at Matrix Capital Management, an investment fund focused on technology and life sciences. Mr. Takhar received a Bachelor of Sciences in Economics and Mathematics from the Massachusetts Institute of Technology.